



Citi Pharma Limited

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

September 12, 2025

DISCLOSURE OF MATERIAL INFORMATION

Dear Sir

In compliance with Section 96 of the Securities Act, 2015 and clause 5.6.1 of the PSX Regulations, we hereby convey the following information.

Citi Pharma Limited is pleased to announce that its wholly owned subsidiary, Citi Veterinary Limited, has formally commenced trading operations. The Company is initially launching 32 veterinary products including vaccines, with Letters of Credit (LCs) already established for 8 products to ensure timely availability and supply.

For the financial year 2025-26, Citi Veterinary Limited is projecting an expected turnover of approximately PKR 1,500 million with a gross profit margin of 13%. The Company's strong and long-standing supply partnerships in China will play a vital role in ensuring consistent and reliable supply availability in Pakistan's veterinary healthcare market. Our supply chain partners in China have already established dedicated veterinary divisions and have strongly encouraged Citi Veterinary Limited to tap into Pakistan's veterinary sector. Looking ahead, Citi Veterinary Limited is ambitiously planning to scale operations and achieve a turnover target of PKR 10 billion within the next three years.

On the production side, Citi Veterinary Limited has already submitted the layout plan with the Drug Regulatory Authority of Pakistan (DRAP) and the inspection is expected to be held in December 2025. Allied facilities are already in place, and the Company has acquired locally manufactured machinery while also establishing LCs for the import of additional machinery. With these measures in place, the production facility is expected to be ready for use, with trial production commencing by the end of Q4 of FY 2025-26 and the commercial production initiating from the start of FY 2026-27. Furthermore, the Company is planning to establish Pakistan's first dedicated veterinary API plant during FY 2026-27, marking a pioneering step in the country's veterinary pharmaceutical industry.

Upon commencement of in-house production, the Company anticipates an increase in its gross profit margin to approximately 25%, reflecting stronger value addition and enhanced operational efficiency.

Citi Veterinary Limited is confident that this milestone will mark the beginning of a new growth chapter, contributing significantly to Pakistan's veterinary pharmaceutical industry and further strengthening Citi Pharma Limited's diversified portfolio.

Sincerely


Ghulam Dastgeer
Company Secretary



CC:
Executive Director/HOD
Offsite-II Department, Supervision Division
63-NIC Building, Jinnah Avenue
Islamabad



58B - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory: +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk